Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges

被引：11
|
作者：
Blumer, Ian [1 ,2 ]
Clement, Maureen [3 ]
机构：
[1] Charles H Best Diabet Ctr, Ajax, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Univ British Columbia, Diabet Educ Ctr, Vernon, BC, Canada
来源：
CLINICAL THERAPEUTICS | 2017年 / 39卷 / 08期
关键词：
basal insulin; hypoglycemia; management; type; 2; diabetes; TO-TARGET TRIAL; PATIENT-REPORTED OUTCOMES; GLARGINE; 100; UNITS/ML; GLYCEMIC CONTROL; COGNITIVE FUNCTION; GLUCOSE CONTROL; NPH INSULIN; PEOPLE; DEGLUDEC; RISK;
D O I：
10.1016/j.clinthera.2016.09.020
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hypoglycemia in people with insulin-treated type 2 diabetes can be a limiting factor for management and a barrier to optimizing glycemic control. Even mild episodes of hypoglycemia can affect an individual's quality of life, and fear of hypoglycemia can lead to underinsulinization. This article explores the prevalence and consequences of hypoglycemia in people with type 2 diabetes with a focus on those who use basal insulins, offering strategies for prevention and management. It also discusses the benefits and challenges associated with new basal insulins, and their potential role in reducing hypoglycemia risk. (C) 2017 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码：S1 / S11
页数：11
相关论文
共 50 条
  • [1] Economic Burden of Hypoglycemia With Basal Insulin in Type 2 Diabetes
    Fonseca, Vivian
    Chou, Engels
    Chung, Hsing-Wen
    Gerrits, Charles
    AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (02): : 114 - +
  • [2] Insulins for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1571): : 65 - 68
  • [3] Switching basal insulins in type 2 diabetes: practical recommendations for health care providers
    Anderson, Sarah L.
    Trujillo, Jennifer M.
    Anderson, John E.
    Tanenberg, Robert J.
    POSTGRADUATE MEDICINE, 2018, 130 (02) : 229 - 238
  • [4] The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino, Maria Ida
    Petrizzo, Michela
    Capuano, Annalisa
    Giugliano, Dario
    Esposito, Katherine
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (06) : 799 - 808
  • [5] The rise of weekly insulins: addressing the challenges of type 2 diabetes care in Brazil
    Vianna, Andre Gustavo Daher
    Alves, Daniely Freitas
    Assmann, Tais Silveira
    Rea, Rosangela Roginski
    DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01):
  • [6] Newer insulins in type 2 diabetes
    Gale, Edwin A. M.
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [7] Advances in newer basal and bolus insulins: impact on type 1 diabetes
    Vliebergh, Joke
    Lefever, Eveline
    Mathieu, Chantal
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2021, 28 (01) : 1 - 7
  • [8] Pharmacodynamics of basal insulins NPH, glargine and detemir in type 2 diabetes mellitus: effects of adiposity
    Porcellati, F.
    Lucidi, P.
    Rossetti, P.
    Candeloro, P.
    Andreoli, A. Marinelli
    Cioli, P.
    Bolli, G. B.
    Fanelli, C. G.
    DIABETOLOGIA, 2011, 54 : S429 - S429
  • [9] Pharmacodynamics of Basal Insulins NPH, Glargine and Detemir in Type 2 Diabetes Mellitus: Effects of Adiposity
    Porcellati, Francesca
    Lucidi, Paola
    Rossetti, Paolo
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Cioli, Patrizia
    Fede, Raffaela
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES, 2011, 60 : A259 - A259
  • [10] Modern basal insulins: an ongoing story or the start of a new era?
    Dedov, I. I.
    DIABETES MELLITUS, 2015, 18 (04): : 5 - 11
12345